962 resultados para B-7
Resumo:
INTRODUCTION: Peripheral arterial disease (PAD) is associated with systemic impaired flow-mediated dilation (FMD) and increased risk for cardiovascular events. Decreased FMD may be caused by a decrease in arterial shear stress due to claudication and inflammation due to muscle ischemia and reperfusion. We assumed that endovascular revascularization of lower limb arterial obstructions ameliorates FMD and lowers inflammation through improvement of peripheral perfusion. METHODS: The study was a prospective, open, randomized, controlled, single-center follow-up evaluation assessing the effect of endovascular revascularization on brachial artery reactivity (FMD) measured by ultrasound, white blood cell (WBC) count, high-sensitive C-reactive protein (hs-CRP), and fibrinogen. We investigated 33 patients (23 men) with chronic and stable PAD (Rutherford 2 to 3) due to femoropopliteal obstruction. Variables were assessed at baseline and after 4 weeks in 17 patients (group A) who underwent endovascular revascularization and best medical treatment, and in 16 patients (group B) who received best medical treatment only. RESULTS: FMD did not differ between group A and B (4.96% +/- 1.86% vs 4.60% +/- 2.95%; P = .87) at baseline. It significantly improved after revascularization in group A (6.44% +/- 2.88%; P = .02) compared with group B at 4 weeks of follow-up (4.53% +/- 3.17%; P = .92), where it remained unchanged. The baseline ankle-brachial index (ABI) was similar for group A and B (0.63 +/- 0.15 vs 0.66 +/- 0.10; P = .36). At 4 weeks of follow-up, ABI was significantly increased in group A (1.05 +/- 0.15; P = .0004) but remained unchanged in group B (0.62 +/- 0.1). WBC counts of the two groups were comparable at baseline (group A: 7.6 +/- 2.26 x 10(6)/mL and group B: 7.8 +/- 2.02 x 10(6)/mL, P = .81). In group A, the leukocyte count significantly decreased after angioplasty from 7.6 +/- 2.26 to 6.89 +/- 1.35 x 10(6)/mL (P = .03). For group B, WBC count did not differ significantly compared with baseline (7.76 +/- 2.64 x 10(6)/mL; P = .94). No effects were observed on hs-CRP or fibrinogen from endovascular therapy. CONCLUSION: Endovascular revascularization with reestablishment of peripheral arterial perfusion improves FMD and reduces WBC count in patients with claudication. Revascularization may therefore have clinical implications beyond relief of symptoms, for example, reducing oxidative stress caused by repeated muscle ischemia or increased shear stress due to improved ambulatory activity.
Resumo:
A novel and efficient regioselective synthesis of various arylated highly congested 7-aryl-5-methylsulfanylindan-4-carbonitriles (3a-(), methyl 7-aryl-5-methylsulfanylindan-4-carboxylates (lOa-e) and 7-aryl-5-methylsulfanylindan-4-carboxylic acids (lla-e) through base-catalyzed reaction of 6-aryl-4-methylsulfanyl-2-oxo-2H-pyran-3-carbonitriles (la-() and methyl 6-aryl-4-methylsulfanyl-2-oxo-2Hpyran-3-carboxylates (9a-e) by cyclopentanone (2) has been delineated. The synthetic potential of 2-pyranone was explored further to generate mo'iecular diversity using 6-aryl-4-secamino- 2-oxo-2H-pyran-3-carbonitriles (7a-h), 5,6-diaryl-4-methylsulfanyl-2-oxo2H-pyran-3-carbonitriles (Sa,b) and methyl 5,6-diaryl-4- methylsulfanyl-2-oxo-2H-pyran-3-carboxylates (12a,b) as precursors for the ring transformation by cyclopentanone to assess the effects of substituents on the course of the reaction to obtain highly congested indans, 6,7diaryl-5-methylsulfanylindan-4-carbonitriles (6a,b), 7-aryl-5-(piperidin-I-yl)indancarbonitriles (8a-h) and methyl 6,7-4- diaryl-5-methylsulfanylindan-4-carboxylate 13a,b).
Resumo:
von S. M. Dubnow. Autoris. Übers. aus dem Russ. von I. Friedländer
Resumo:
von S. M. Dubnow. Autoris. Übers. aus d. Russ. von Israel Friedländer
Resumo:
[Verf.: Joseph Franz Molitor]
Resumo:
El propósito de este trabajo fue evaluar la incidencia de la concentración de nitrógeno prontamente asimilable (NPA) sobre la velocidad y duración de la fermentación alcohólica de los mostos de uva. El experimento se diseñó con tres tratamientos (A=testigo; B=agregado de PO4H(NH4)2 50 mg/L; C=agregado de PO4H(NH4)2 100 mg/L) y cuatro repeticiones. Se realizaron microvinificaciones con jugo de uva pasteurizado var. Chardonnay, inoculado con Saccharomyces cerevisiae cepa FCA 32. La fermentación se condujo a 25 °C. La concentración de NPA fue medida por titulación en medio formol. La velocidad de fermentación fue determinada por pérdida de peso. La velocidad máxima de fermentación se alcanzó al tercer día. Existen diferencias significativas entre la velocidad máxima alcanzada por el testigo y por los tratamientos B y C pero no hay diferencias significativas entre las velocidades máximas alcanzadas por los tratamientos B y C. La velocidad máxima de fermentación alcanzada por el tratamiento B (agregado de 50 mg/L de PO4H(NH4)2) fue 57 % superior respecto del testigo, mientras que el tratamiento C (agregado de 100 mg/L de PO4H(NH4)2) fue 53 % superior respecto del mismo testigo La velocidad máxima de fermentación aumentó con la adición de nitrógeno, pero no se observan diferencias entre las distintas dosis empleadas. La duración media de la fermentación resulta significativamente diferente para los tres tratamientos: 9.25 días para el testigo, 7.5 días para el tratamiento B y 6.25 días para el tratamiento C. El agregado de PO4H(NH4)2 disminuye la duración de la fermentación en las condiciones de trabajo. La duración de la fermentación del tratamiento B (agregado de 50 mg/L de PO4H(NH4)2) fue del 81 % respecto del testigo 100 %, mientras que el tratamiento C (agregado de 100 mg/L de PO4H(NH4)2) fue del 67 %, respecto del mismo testigo.